Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
P08217
UPID:
CEL2A_HUMAN
Alternative names:
Elastase-2A
Alternative UPACC:
P08217; B2R5I4; Q14243
Background:
Chymotrypsin-like elastase family member 2A, also known as Elastase-2A, plays a crucial role in enhancing insulin signaling and glucose metabolism. Its activity in plasma contributes to reducing platelet hyperactivation and increasing insulin sensitivity.
Therapeutic significance:
Given its involvement in abdominal obesity-metabolic syndrome 4, characterized by obesity, hypertension, and type 2 diabetes, Elastase-2A represents a promising target for therapeutic intervention in metabolic disorders.